Clinical Trials Logo

Chronic Idiopathic Constipation clinical trials

View clinical trials related to Chronic Idiopathic Constipation.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04458675 Completed - Clinical trials for Chronic Idiopathic Constipation

Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC)

CIC
Start date: July 26, 2018
Phase: Phase 4
Study type: Interventional

The was performed to assess the safety and efficacy of the vibrant capsule vs. placebo for the treatment of subjects with functional Constipation.

NCT ID: NCT03879239 Completed - Clinical trials for Chronic Idiopathic Constipation

Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation

Vibrant
Start date: March 30, 2019
Phase: N/A
Study type: Interventional

The study is a prospective, randomized, multicenter, adaptive design, double blinded, placebo-controlled study, to evaluate the efficacy and safety of Vibrant Capsule vs. placebo in relieving constipation in subjects with Chronic Idiopathic Constipation.

NCT ID: NCT03551873 Completed - Clinical trials for Chronic Idiopathic Constipation

A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

Start date: June 21, 2018
Phase:
Study type: Observational

This is a multi-center, open-label study evaluating pharmacokinetics of TRULANCE® (plecanatide) in breast milk of lactating women treated with TRULANCE

NCT ID: NCT03120520 Completed - Clinical trials for Chronic Idiopathic Constipation

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

Start date: January 2017
Phase: Phase 2
Study type: Interventional

This is a study of efficacy and safety of Plecanatide in pediatric subjects aged 12 to < 18 years diagnosed with Chronic Idiopathic Constipation.

NCT ID: NCT03097861 Completed - Clinical trials for Chronic Idiopathic Constipation

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Start date: March 13, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo, when administered orally in participants with Chronic Idiopathic Constipation (CIC).

NCT ID: NCT03054506 Completed - Constipation Clinical Trials

The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

Start date: March 7, 2017
Phase: N/A
Study type: Interventional

Constipation is a common gastrointestinal motility disorder that is often chronic, negatively affects patients' daily lives. Constipation occurs when bowel movements become difficult or less frequent.This study is being done to study the effectiveness of the hydrogel capsule, CSP01, compared to the active control (carboxymethylcellulose) and placebo (non-medicine sugar pill), to relieve constipation among subjects with chronic idiopathic constipation (CIC) or with irritable bowel syndrome with constipation (IBS-C).

NCT ID: NCT02819310 Completed - Constipation Clinical Trials

An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults

Start date: June 2016
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety of chronic use of BLI400 laxative in constipated adults.

NCT ID: NCT02819297 Completed - Constipation Clinical Trials

BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Start date: June 2016
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus placebo in constipated adults.

NCT ID: NCT02695719 Completed - Clinical trials for Chronic Idiopathic Constipation

Lubiprostone for Treatment of Chronic Idiopathic Constipation

Start date: April 14, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of oral administration of lubiprostone 24 μg twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.

NCT ID: NCT02590432 Completed - Clinical trials for Chronic Idiopathic Constipation

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Start date: November 1, 2015
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to assess the potential of LINZESS® (linaclotide) treatment to induce the development of anti-drug antibodies (ADAs). The secondary objectives are to provide additional evidence supporting the long-term safety and efficacy of linaclotide in adult irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) participants and to evaluate lower doses of linaclotide.